Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BIOlogical Successful Tapering Prediction study
NL-OMON42567Withdrawn
- Sponsor
- Sint Maartenskliniek
- Start
- Nov 2015
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label trial of abatacept, adalimumab, certolizumab pegol, etanercept, golimumab and 1 more in rheumatoid arthritis (RA), psoriatic arthritis (PsA) and spondyloarthritis (SpA) (6 cohorts), sponsored by Sint Maartenskliniek. Primary endpoint: Successful dose tapering at 6 months. Planned start Nov 2015; status: withdrawn.
02
Drugs
03
Conditions
rheumatoid arthritis (RA)psoriatic arthritis (PsA)spondyloarthritis (SpA)
Beyond the preview
Go deeper on NL-OMON42567.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON42567.